Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient Demography

From: Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients

Characteristic Study A Study B
Number of subjects screened 33 206
Number of subjects randomised 33 75*
Mean age (years) (sd) 40.2 (14.3) 36.4 (12.5)
Sex: Males/females % 48/52 48/52
Mean % predicted FEV1 (sd) 80.5 (12.4) 82.8 (17.0)
Mean % reversibility (sd) 18.9 (6.9) 28.7 (17.6)
Duration of asthma (n):   
< 5 years 2 5
10–20 years 9 31
>20 years 22 39
Current smoker, n (%) 1 (3%) 12 (16%)
Dose of ICS at screening for randomised patients (n)   
BDP: 200 mcg bd/400 mcg bd/500 mcg bd 2/1/0 5/23/15
Budesonide: 200 mcg bd/300 mcg bd/400 mcg bd/600 mcg bd 10/1/13/0 0/0/21/1
FP: 100 mcg/250 mcg bd 2/4 2/8
  1. * the majority of screen failures demonstrated insufficient bronchodilator reversibility